Prognosis of hospitalized patients with cirrhosis and acute kidney disease was written by Wong, Florence;Garcia-Tsao, Guadalupe;Reddy, K. Rajender;O’Leary, Jacqueline G.;Kamath, Patrick S.;Tandon, Puneeta;Lai, Jennifer C.;Vargas, Hugo E.;Biggins, Scott W.;Fallon, Michael B.;Thuluvath, Paul J.;Maliakkal, Benedict J.;Subramanian, Ram;Thacker, Leroy;Bajaj, Jasmohan S.. And the article was included in Liver International in 2022.COA of Formula: C43H51N3O11 This article mentions the following:
The prognosis of acute kidney disease (AKD), defined as a glomerular filtration rate of <60 mL/min/1.73 m2 or a rise in serum creatinine (sCr) of <50% for <3 mo, is not clearly known. To study the prevalence, predictive factors and clin. outcomes in hospitalized cirrhotic patients with AKD. The North American Consortium for the Study of End-Stage Liver Disease prospectively enrolled hospitalized decompensated cirrhotic patients. Patients were separated into those with normal renal function (controls or C), AKD or stage 1 AKI as their worst renal dysfunction per International Club of Ascites definition and compared. Parameters assessed included demographics, laboratory data, haemodynamics, renal and patient outcomes. 1244 Patients with cirrhosis and ascites (C: 704 or 57%; AKD: 176 or 14%; stage 1 AKI: 364 or 29%) with similar demographics were enrolled. AKD patients had similar baseline sCr but higher hospital admission in the previous 6 mo, and higher peak sCr, compared to controls, with their peak sCr being lower than that in stage 1 AKI patients (all P < .0001). The in-hospital and 30-day survival for AKD patients were intermediary between that for controls and stage 1 AKI patients (96% vs 91% vs 86%, P < .0001). The strongest predictors for AKD development while in hospital were the presence of a second infection (OR: 2.44) and diabetes (OR: 1.53). Patients with AKD had intermediate outcomes between stage 1 AKI and controls. AKD patients, especially those with diabetes and a second infection, need careful monitoring and prompt treatment for AKD to prevent neg. outcomes. In the experiment, the researchers used many compounds, for example, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione (cas: 80621-81-4COA of Formula: C43H51N3O11).
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione (cas: 80621-81-4) belongs to benzofurans derivatives. Benzofurans are compounds with a planar structure having 10 pi electrons that include the lone pair on oxygen atom, which makes it more susceptible to electrophilic attack. Substituted benzofurans find applications such as fluorescent sensors, oxidants, in drug discovery, and in another field of chemistry and agriculture.COA of Formula: C43H51N3O11
Referemce:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem